Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 153 Jul 18 – Oct 15, 2026
- Disclosed funding
- $5.2B 123 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| I InduProCompany profile Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease | $77M | Series B | Biotech | United States | Investors | |
| R RemepyCompany profile Develops Hybrid Drugs combining prescription medicines with AI-driven therapeutic apps Develops Hybrid Drugs combining prescription medicines with AI-driven therapeutic apps | $36M | Series A | Biotech | Israel | Investors | |
| A AquaNabCompany profile AquaNab develops nanoantibody-based treatments for fish diseases, starting with sea lice in salmon farming. AquaNab develops nanoantibody-based treatments for fish diseases, starting with sea lice in salmon farming. | Undisclosed | Undisclosed | Biotech | Germany | Investors | |
| E ExobiosphereCompany profile Exobiosphere runs automated experiments in microgravity to help pharmaceutical and biotechnology researchers study disease and test drug candidates. Exobiosphere runs automated experiments in microgravity to help pharmaceutical and biotechnology researchers study disease and test drug candidates. | €1M | Jeune Entreprise Innovante grantUndisclosed | Biotech | Luxembourg | Investors | |
| VT Vaderis TherapeuticsCompany profile Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia | $152M | Series B | Biotech | Switzerland | Investors | |
| I InfinimmuneCompany profile Develops human-derived antibody therapeutics for atopic dermatitis and inflammatory disease Develops human-derived antibody therapeutics for atopic dermatitis and inflammatory disease | $75M | Series A | Biotech | United States | Investors | |
| EB Epicrispr BiotechnologiesCompany profile Develops programmable epigenetic medicines to treat genetic diseases like FSHD Develops programmable epigenetic medicines to treat genetic diseases like FSHD | $90M | Series CSeries C+ | Biotech | United States | Investors | |
| AB Aureka BiotechnologiesCompany profile Builds biological foundation models and closed-loop infrastructure for drug discovery Builds biological foundation models and closed-loop infrastructure for drug discovery | $100M | Series B | Biotech | United States | Investors | |
| RB Remedium BioCompany profile Develops durable protein therapeutics via gene therapy for chronic diseases Develops durable protein therapeutics via gene therapy for chronic diseases | $10M | Series A | Biotech | United States | Investors | |
| S SkinBitCompany profile Provides full-body skin scanning technology for early skin cancer detection and screening Provides full-body skin scanning technology for early skin cancer detection and screening | $6M | Pre-SeedPre-seed | Biotech, Healthtech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 18, 2026
- 1Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
10rounds0led - 2RA Capital Management
Circle Pharma, Inc., Solstice Oncology, Superluminal Medicines
8rounds2led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
6rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
6rounds2led - 5Oxford Science Enterprises
OMass Therapeutics, ReEmerge, Inc., Vivid Dx
5rounds0led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.